news

Regeneron and Intellia collaborate to discover CRISPR/Cas therapeutics

Posted: 12 April 2016 | Victoria White, Digital Content Producer | No comments yet

In addition to the discovery, development and commercialisation of new therapies, the companies will focus on technology development of the CRISPR/Cas platform…

Regeneron and Intellia Therapeutics are to collaborate to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development.

In addition to the discovery, development and commercialisation of new therapies, the companies will focus on technology development of the CRISPR/Cas platform.

Under the terms of the six-year agreement, Regeneron has the exclusive right to discover and develop CRISPR-based products against up to 10 targets, focused primarily on therapies for a broad range of diseases that may be treated by editing genes in the liver. Of the 10 targets, Regeneron can select up to five non-liver targets. Non-liver targets from Intellia’s ongoing and planned research, as well as targets included in another Intellia collaboration, are excluded from this collaboration.

 

Reserve your FREE place

 


Reduce preclinical failures with smarter off-target profiling

24 September 2025 | 15:00PM BST | FREE Webinar

Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.

What you’ll learn:

  • Approaches for prioritizing follow-up studies and refining risk mitigation strategies
  • How to interpret hit profiles from binding and functional assays
  • Strategies for identifying organ systems at risk based on target activity modulation
  • How to use visualization tools to assess safety margins and compare compound profiles

Register Now – It’s Free!

 

Intellia will receive a $75 million upfront payment and is eligible to receive significant milestone and royalty payments on potential Regeneron products. Intellia and Regeneron have agreed to co-develop and co-commercialise a certain number of targets that are generated during the collaboration. Transthyretin amyloidosis is the first target to be jointly developed by the companies. Regeneron has also agreed to invest up to $50 million in Intellia’s next equity financing.

Collaboration holds ‘real promise’ for serious diseases

Commenting on the collaboration, George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories, said: “Our industry-leading human genetics research with the Regeneron Genetics Center is already identifying important genetic targets, building on our long-standing expertise in genetic engineering. We believe combining these capabilities with Intellia’s technology holds real promise for serious diseases that have been historically difficult to address, and expands our ability to help patients where antibody-based therapies may not be the optimal solution.”

Nessan Bermingham, Ph.D., Chief Executive Officer and Founder, Intellia Therapeutics, added: “We are excited to be partnering with Regeneron, an industry leader in human genetics research. Regeneron’s focus on advancing science to medicine is an excellent fit with Intellia’s approach, and together, we aim to bring potential cures to patients who are suffering from life-threatening rare diseases and genetic diseases.”

Related topics

Related organisations
,

Leave a Reply

Your email address will not be published. Required fields are marked *